A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration approval for a form of breast cancer, the first U.S. approval for a drug for which the companies have high expectations.
The FDA announced Friday that it had approved the drug, which will be marketed as Datroway, for certain patients with advanced breast cancer. Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form of breast cancer last month, its first regulatory green light.
The list price of Datroway in the United States is approximately $4,900 per 100-milligram vial, and the recommended dose of the drug is 6 milligrams per kilogram of the patient’s weight every three weeks.
Already have an account? Log in
See all packages
Adrien Brody and Felicity Jones in 'The Brutalist'.A24 The Brutalist Director Brady Corbet discusses backlash…
A new study on Monday highlighted the potential benefits of popular diabetes drugs on a…
President Joe Biden pardoned several members of his immediate family Monday in the final minutes…
CNN — The federal government will recognize only two genders, male and female, under an…
Asian stock markets posted modest gains Tuesday after President Donald Trump said he was considering…
As for seating charts, that was a tricky question.There's only room for about 800 seats…